DE69430126D1 - Cyclodextrine zur reduzierung des durch zytotoxische substanzen verursachten gefässaustritts - Google Patents

Cyclodextrine zur reduzierung des durch zytotoxische substanzen verursachten gefässaustritts

Info

Publication number
DE69430126D1
DE69430126D1 DE69430126T DE69430126T DE69430126D1 DE 69430126 D1 DE69430126 D1 DE 69430126D1 DE 69430126 T DE69430126 T DE 69430126T DE 69430126 T DE69430126 T DE 69430126T DE 69430126 D1 DE69430126 D1 DE 69430126D1
Authority
DE
Germany
Prior art keywords
compositions
cytotoxic
cyclodextrin
reducing
ulceration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69430126T
Other languages
English (en)
Other versions
DE69430126T2 (de
Inventor
Ph Rubinfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Pharmaceuticals Inc
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Application granted granted Critical
Publication of DE69430126D1 publication Critical patent/DE69430126D1/de
Publication of DE69430126T2 publication Critical patent/DE69430126T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69430126T 1993-09-03 1994-09-02 Cyclodextrine zur reduzierung des durch zytotoxische substanzen verursachten gefässaustritts Expired - Fee Related DE69430126T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11672493A 1993-09-03 1993-09-03
US08/297,249 US5602112A (en) 1992-06-19 1994-08-26 Pharmaceutical formulation
PCT/US1994/009879 WO1995006485A1 (en) 1993-09-03 1994-09-02 Improved pharmaceutical formulation

Publications (2)

Publication Number Publication Date
DE69430126D1 true DE69430126D1 (de) 2002-04-18
DE69430126T2 DE69430126T2 (de) 2002-08-01

Family

ID=26814548

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430126T Expired - Fee Related DE69430126T2 (de) 1993-09-03 1994-09-02 Cyclodextrine zur reduzierung des durch zytotoxische substanzen verursachten gefässaustritts

Country Status (13)

Country Link
US (6) US5602112A (de)
EP (1) EP0717638B1 (de)
JP (1) JPH09502185A (de)
AT (1) ATE214290T1 (de)
AU (1) AU7718694A (de)
CA (1) CA2172159C (de)
DE (1) DE69430126T2 (de)
DK (1) DK0717638T3 (de)
ES (1) ES2171462T3 (de)
HU (1) HUT73778A (de)
IL (1) IL110825A0 (de)
PT (1) PT717638E (de)
WO (1) WO1995006485A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5756483A (en) * 1993-03-26 1998-05-26 Merkus; Franciscus W. H. M. Pharmaceutical compositions for intranasal administration of apomorphine
NZ505584A (en) 1996-05-24 2002-04-26 Univ British Columbia Delivery of a therapeutic agent to the smooth muscle cells of a body passageway via an adventia
BR9713661A (pt) 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
HUP9701945A3 (en) * 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
GB9921958D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
GB9921954D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
CA2726789A1 (en) 2000-02-05 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
AU2001259298A1 (en) * 2000-05-02 2001-11-12 Advanced Medicine, Inc. Polyacid glycopeptide derivatives
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US6828299B2 (en) 2000-06-22 2004-12-07 Theravance, Inc. Polyhydroxy glycopeptide derivatives
AU2001259303A1 (en) * 2000-06-22 2002-01-02 Advanced Medicine, Inc. Glycopeptide carboxy-saccharide derivatives
US6872804B2 (en) * 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
IT1318689B1 (it) * 2000-09-12 2003-08-27 Pharmacia & Upjohn Spa Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla
US6884885B2 (en) 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
EP1610751A4 (de) * 2001-04-26 2006-05-24 Univ Texas Therapeutisches mittel/ligand-konjugat-zusammensetzungen, ihre syntheseverfahren und ihre anwendung
US6528076B2 (en) 2001-07-06 2003-03-04 Magic Herb Corp. Topical compositions and methods for treating pain
GB0127677D0 (en) * 2001-11-19 2002-01-09 Vianex S A Inclusion complex
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US6828311B2 (en) 2002-05-29 2004-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Formulation for the parenteral application of a sodium channel blocker
BR0314068A (pt) * 2002-09-05 2005-07-05 Bharat Serums & Vaccines Ltd Processo para a preparação de uma composição estável com baixo nìvel de toxicidade; composição estável que contém oxazafosforina; uso de uma composição estável que contém oxazafosforina; e método de tratamento de uma doença maligna
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
WO2005082416A2 (en) * 2004-01-30 2005-09-09 Pfizer Products Inc. Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
WO2007110709A2 (en) * 2005-10-14 2007-10-04 Janssen Pharmaceutica, N.V. Formulations of tipifarnib for intravenous administration
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
CN100486645C (zh) 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN101528215B (zh) 2006-10-20 2011-10-19 艾科斯有限公司 Chk1抑制剂和环糊精的组合物
WO2009132352A1 (en) * 2008-04-25 2009-10-29 Rhode Island Hospital Active sunscreen composition
RU2734236C2 (ru) 2009-02-25 2020-10-13 Софткемо Фарма Корп. Композиции бендамустина и циклополисахарида
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
EA022890B1 (ru) 2009-05-29 2016-03-31 Сидекс Фармасьютикалз, Инк. Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их применения
US20110015245A1 (en) * 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
KR20140078619A (ko) * 2011-09-18 2014-06-25 유로-셀띠끄 소시에떼 아노님 약학적 조성물
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2919837A1 (en) * 2013-08-02 2015-02-05 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
WO2015061206A2 (en) 2013-10-21 2015-04-30 North Carolina State University Methods and constructs for compound delivery
RU2587716C2 (ru) * 2014-01-14 2016-06-20 Борис Игоревич Круглый Стабильный фармацевтический состав на основе актиномицина д для инъекций
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735189B2 (de) * 1972-01-06 1982-07-27
US4024223A (en) * 1972-11-11 1977-05-17 Teijin Limited Stripe composition and method of reducing smell associated therewith
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
JPS54115368A (en) * 1978-03-01 1979-09-07 Ono Pharmaceut Co Ltd Prostaglandin i2 analog, its preparation, and drug composition containing it as active constituent
DE2912409A1 (de) * 1978-03-31 1979-10-11 Ono Pharmaceutical Co 6,9-methano-pgi tief 2 -analoge
US4352793A (en) * 1979-04-26 1982-10-05 Sumitomo Chemical Company, Limited Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin
JPS6033430B2 (ja) * 1980-05-12 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物
IE52500B1 (en) * 1981-01-23 1987-11-25 Wellcome Found Chemical complex
JPS5813541A (ja) * 1981-07-16 1983-01-26 Kureha Chem Ind Co Ltd エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物
US4407795A (en) * 1981-07-16 1983-10-04 American Cyanamid Company Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
DE3315356A1 (de) * 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka Verwendung von prostaglandinanalogen
US4425336A (en) * 1982-05-24 1984-01-10 Key Pharmaceuticals, Inc. 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
US4424209A (en) * 1982-06-21 1984-01-03 Key Pharmaceuticals, Inc. 3,4-Di-isobutyryloxy-N- 3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phenethylamine cyclodextrin complexes
JPS5910510A (ja) * 1982-07-08 1984-01-20 Nippon Zenyaku Kogyo Kk 低刺激性チアムリン注射剤
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
HU190818B (en) * 1982-11-09 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing complexes of piperonyl-butoxide-cyclodextrin
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
US4751095A (en) * 1983-07-28 1988-06-14 Karl Curtis L Aspartame stabilization with cyclodextrin
JPS6081166A (ja) * 1983-10-11 1985-05-09 Fujisawa Pharmaceut Co Ltd ２−ニトロオキシメチル−６−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
US4675395A (en) * 1984-03-14 1987-06-23 Seiwa Technological Laboratories Limited Cyclodextrin inclusion compound and process for its preparation
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPS61207380A (ja) * 1985-03-11 1986-09-13 Taiyo Yakuhin Kogyo Kk モベンゾキサミンの経口製剤
JPS61286318A (ja) * 1985-06-13 1986-12-16 Ichiro Shibauchi 浴剤の製造方法
US4663316A (en) * 1985-06-28 1987-05-05 Warner-Lambert Company Antibiotic clathrates and pharmaceutical compositions thereof
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
US4623641A (en) * 1985-09-09 1986-11-18 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
JP3176716B2 (ja) * 1991-06-21 2001-06-18 武田薬品工業株式会社 溶解性が向上した難水溶性薬物組成物
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途

Also Published As

Publication number Publication date
US6284747B1 (en) 2001-09-04
WO1995006485A1 (en) 1995-03-09
HU9600612D0 (en) 1996-05-28
US5602112A (en) 1997-02-11
US5804568A (en) 1998-09-08
ATE214290T1 (de) 2002-03-15
EP0717638B1 (de) 2002-03-13
US6218374B1 (en) 2001-04-17
JPH09502185A (ja) 1997-03-04
EP0717638A1 (de) 1996-06-26
US6583125B2 (en) 2003-06-24
IL110825A0 (en) 1995-05-26
US6048845A (en) 2000-04-11
AU7718694A (en) 1995-03-22
HUT73778A (en) 1996-09-30
CA2172159C (en) 2003-07-29
DK0717638T3 (da) 2002-07-01
PT717638E (pt) 2002-07-31
ES2171462T3 (es) 2002-09-16
DE69430126T2 (de) 2002-08-01
CA2172159A1 (en) 1995-03-09
US20020058634A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
DE69430126T2 (de) Cyclodextrine zur reduzierung des durch zytotoxische substanzen verursachten gefässaustritts
KR950702994A (ko) 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol)
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
CA2159450A1 (en) 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors
KR950016783A (ko) 조절 방출용 약학 조성물
TR199901127T2 (xx) Antibakteriyel etkili 6-O-ikameli ketolitler.
WO2001072721A3 (en) Synergistic methods and compositions for treating cancer
WO2000044761A3 (en) Ketolide antibiotics
DE69413237D1 (en) Plättchenaggregationsinhibitoren
AU678344B2 (en) Lipophilic oligosaccharide antibiotic salt compositions
KR987000322A (ko) 신규 안트라시클린 화합물 유도체 및 이를 함유하는 의약 제제(novel anthracycline compound derivative and pharmaceutical preparation containing the same)
KR960013370A (ko) 트리글리세리드 과다 방지 조성물
BR0212036A (pt) Composições farmacêuticas compreendendo conjugados de polissacarìdeos para a inibição da metástase ou prevenção da recorrência de tumor maligno
CA2140927A1 (en) Platelet aggregation inhibitors
WO1996023771A3 (en) Platelet aggregation inhibitors
ATE140458T1 (de) Imidazole derivate und diese enthaltende arzneimittel
NZ242155A (en) 4-aminobutoxyphosphonic acid derivatives, their preparation using streptomyces platensis, and pharmaceutical compositions
WO1999057125A3 (en) Hygromycin a derivatives
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
TNSN00211A1 (fr) Derives d'hygromycine a nouveaux, compositions les contenant et leur utilisation
DE69902925D1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen
WO2002024711A1 (fr) Nouveaux composes bicycliques thiazole
BG103985A (en) Multicyclic derivatives of erythromycin
AR004223A1 (es) Composiciones para inhibir la agregacion de plaquetas y el uso de las mismas en la manufactura de un medicamento.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SUPERGEN, INC., DUBLIN, CALIF., US

8339 Ceased/non-payment of the annual fee